Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 21, 2015 10:13 AM ET

Biotechnology

Company Overview of Open Monoclonal Technology, Inc.

Company Overview

Open Monoclonal Technology, Inc. operates as a biotechnology company. It offers OmniRat, an antibody platform that generates human monoclonal antibodies based on transgenic rats. Open Monoclonal Technology, Inc. has a strategic alliance with Crystal Bioscience, Inc. The company was founded in 2007 and is based in Palo Alto, California.

2747 Ross Road

Suite A

Palo Alto, CA 94303

United States

Founded in 2007

Phone:

650-224-6835

Fax:

866-591-1712

Key Executives for Open Monoclonal Technology, Inc.

Founder, Chief Executive Officer and Director
Chief Financial Officer
Chief Business Officer
Age: 51
Director of Research
Compensation as of Fiscal Year 2014.

Open Monoclonal Technology, Inc. Key Developments

Open Monoclonal Technology, Inc. Grants OmniAb License to the University of Nottingham

Open Monoclonal Technology, Inc. (OMT) has granted The University of Nottingham a license to OMT's proprietary OmniRat, OmniMouse and OmniFlic platforms for generation of human antibody therapeutics. The university will use the technology for novel cancer antigens. The OmniRat, OmniMouse and OmniFlic platforms will allow to make fully human antibodies that can be fast tracked into the clinic for the benefit of cancer patients.

EMD Serono and Open Monoclonal Technology, Inc. Expand Collaboration to Include Unlimited Access to OmniRat Human Antibody Platform

EMD Serono and Open Monoclonal Technology, Inc. announced expansion of their collaboration agreement from June 2012. Under the terms of the new agreement, EMD Serono will make an upfront payment to secure unlimited access to the OmniRat platform as well as success-based development milestones and royalties. Further details of the contract are not being disclosed.

Symphogen A/S and Open Monoclonal Technology, Inc. Announce Collaboration

Symphogen A/S and Open Monoclonal Technology, Inc. announced an alliance that provides Symphogen with unlimited access to OMT's OmniRat(R) and OmniMouse(R) platforms. Symphogen will use its proprietary B cell-based antibody identification technology, Symplex(TM), and access the diverse immune repertoires generated in OMT's transgenic animals to develop novel human therapeutic candidates.

Similar Private Companies By Industry

Company Name Region
DiaVacs, Inc. United States
EyeCyte, Inc. United States
NaniRx Therapeutics, Inc. United States
Bell Biosystems, Inc. United States
Stem Cell Theranostics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Open Monoclonal Technology, Inc., please visit www.openmonoclonaltechnology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.